Polivy Side Effects Overview
Polivy (polatuzumab vedotin), approved for relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab (BR), shows a differentiated safety profile compared to BR alone. In the phase 3 POLARIX trial, Polivy + BR reduced severe (grade 3-4) neutropenia from 63% (BR alone) to 42%, severe thrombocytopenia from 38% to 24%, and severe anemia from 15% to 11%.[1][2] Febrile neutropenia rates were similar (BR: 19%, Polivy+BR: 18%), but overall peripheral neuropathy was milder and less persistent with Polivy.[1]
Why Fewer Severe Cytopenias?
Polivy's antibody-drug conjugate targets CD79b on B-cells, delivering monomethyl auristatin E selectively, which limits broad myelosuppression compared to chemotherapy-heavy regimens like BR. This leads to lower rates of hospitalization for cytopenias (Polivy+BR: 42% vs. BR: 53%).[2] Patients on Polivy+BR also experienced fewer red blood cell transfusions (31% vs. 41%).[1]
Peripheral Neuropathy: Less Severe and Reversible
Unlike some antibody-drug conjugates (e.g., Enhertu with ado-trastuzumab emtansine), Polivy's neuropathy is mostly grade 1-2 (40% any grade, 4% grade 3+), resolving in 90% of cases within months. This contrasts with higher grade 3+ rates in other CD79b-targeted therapies or vinca alkaloids.[3][4]
Comparison to Other Lymphoma Treatments
| Regimen | Severe Neutropenia | Severe Thrombocytopenia | Febrile Neutropenia | Source |
|---------|---------------------|--------------------------|---------------------|--------|
| Polivy + BR | 42% | 24% | 18% | [1] |
| BR alone | 63% | 38% | 19% | [1] |
| R-CHOP | 60-70% | 10-20% | 10-15% | [5] |
| Glofitamab (Epcoritamab) | 30-40% | 15% | 5-10% | [6] |
Polivy has lower cytopenia rates than R-CHOP but similar neuropathy to bispecifics like glofitamab, which avoid chemotherapy entirely.[5][6] No direct head-to-head data exists with CAR-T therapies, where cytopenias exceed 80% but are short-term.[7]
Patient-Reported Outcomes
Quality-of-life scores (FACT-Lym) improved faster with Polivy+BR due to reduced fatigue and infections from cytopenias, with 70% maintaining baseline scores vs. 55% on BR.[2] Long-term monitoring shows neuropathy rarely leads to discontinuation (3%).[3]
Risks Still Present
Polivy increases infusion reactions (30% vs. 20%) and pneumonia (13% vs. 9%), though fatalities were comparable.[1] Not recommended for active infections.
Sources:
[1] NEJM: POLARIX Trial (2022)
[2] JCO: Safety Analysis (2022)
[3] FDA Label: Polivy
[4] DrugPatentWatch: Polivy
[5] Lancet Oncology: R-CHOP Meta-Analysis
[6] NEJM: Glofitamab Trial
[7] NEJM: CAR-T ZUMA-1